<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Flip News — pneumococcal-vaccine news</title>
    <link>https://flipnews.co.uk/topics/pneumococcal-vaccine/</link>
    <description>The latest Flip News stories on pneumococcal-vaccine.</description>
    <language>en-GB</language>
    <lastBuildDate>Mon, 05 Oct 2026 20:46:10 GMT</lastBuildDate>
    <atom:link href="https://flipnews.co.uk/topics/pneumococcal-vaccine/feed.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Vaxcyte shares surge as VAX-31 pneumococcal vaccine meets main Phase 3 goals</title>
      <link>https://flipnews.co.uk/health/vaxcyte-vax31-phase-3-results/</link>
      <guid isPermaLink="true">https://flipnews.co.uk/health/vaxcyte-vax31-phase-3-results/</guid>
      <pubDate>Mon, 05 Oct 2026 00:00:00 GMT</pubDate>
      <description>Vaxcyte said its experimental 31-valent pneumococcal vaccine met its main goals in the pivotal OPUS-1 adult trial, sending its shares up 91% before the bell — with an FDA filing planned for the first half of 2028.</description>
      <author>James Calloway</author>
      <category>vaxcyte</category>
      <category>vax-31</category>
      <category>pneumococcal-vaccine</category>
      <source url="https://www.reuters.com/business/healthcare-pharmaceuticals/vaxcyte-shares-surge-pneumococcal-vaccine-meets-main-trial-goals-2026-10-05/">Reuters</source>
    </item>
  </channel>
</rss>
